Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Oct 7 · above the Ichimoku cloud · RSI 41 · MACD below its signal
None of the 29 investors followed here reported a position in HSCS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a HSCS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.5 | -13.7 | -9.8 | -22.4 | -14.4 | 50.3 | -13.1 | 44.5 | 32.7 | -26.1 | +0.0% | ||
| 2025 | -15.5 | 10.3 | -20.8 | 24.3 | 0.8 | 6.2 | -16.8 | 9.3 | 2.1 | -12.4 | -12.1 | 15.3 | −19.1% |
| 2024 | -12.3 | -21.3 | -0.8 | -21.4 | -40.2 | -5.3 | -26.1 | -11.7 | 42.6 | -39.4 | 0.3 | 29.5 | −77.7% |
| 2023 | 154.8 | -36.4 | -27.4 | -10.0 | 12.6 | -9.5 | -3.6 | -19.7 | -39.1 | -41.5 | -2.8 | -29.3 | −79.6% |
| 2022 | -20.0 | -2.7 | -19.2 | 107.2 | -50.1 | -31.1 | −55.2% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 21, 2026 | Simpson AndrewChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 425K | — |
| Nov 27, 2025 | Simpson AndrewChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 70K | — |
| Jul 28, 2025 | Hilz Mark TChief Operating Officer | Sale at price 3.54 per share. | 4.4K | $15.62K |
Buy / hold / sell counts
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.